BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 05, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/2cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Bernstein Research Geoffrey Porges Upgrade Outperform (from market perform) 1% $155.12
Porges also raised his target to $193 from $188 after Alexion said 1Q14 sales of Soliris eculizumab, its sole product, rose 67% to $566.6M and topped the Street's estimate of $560.2M (see BioCentury, April 28). Alexion markets Soliris in almost 50 countries for atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Last month, Alexion began two Phase III trials with Soliris to treat neuromyelitis optica and myasthenia gravis, which...

Read the full 632 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >